01—Abstract
Summary
Summary of the 10-K filed November 21, 2012. Cited figures are marked; the original filing is the authoritative source.
Becton, Dickinson and Company (BDX) reported its 2012 fiscal year-end results, showcasing a global medical technology company with diversified operations across BD Medical, BD Diagnostics, and BD Biosciences segments.
Despite a challenging global economic environment impacting healthcare utilization and pricing pressures, especially in its Biosciences segment, BD demonstrated revenue growth driven by new product launches and strategic acquisitions, including KIESTRA Lab Automation and Sirigen Group. The company continues to invest in research and development and emerging markets, aligning with its strategy to enhance shareholder value through innovation and operational efficiency. Financially, BD reported revenues of $7.7 billiona, a 1.6% increase year-over-year, with solid growth in its Medical and Diagnostics segments.
The company maintained a strong financial position with $2.2 billionb in cash and equivalents. BD also actively returned capital to shareholders through share repurchases and dividends.
Key risks identified include global economic conditions, foreign currency fluctuations, changes in healthcare reimbursement, and the impact of U.S. healthcare reform, notably the impending medical device excise tax. The company is also navigating several significant legal proceedings, including antitrust litigation, which could materially affect its financial results.
02—Key points
Key Highlights
- BD reported total revenues of $7.7 billion for fiscal year 2012, a 1.6% increase from the prior year, driven by volume increases and strategic acquisitions.
- The company's three segments (Medical, Diagnostics, Biosciences) all contributed to revenue growth, with Medical and Diagnostics showing particular strength from new products and acquisitions.
- BD made strategic acquisitions during the year, purchasing KIESTRA Lab Automation for $59 million and Sirigen Group for $64 million to enhance its lab automation and flow cytometry offerings.
- Research and development spending remained robust at $472 million, reflecting BD's commitment to innovation and new product development across its segments.
- The company ended the fiscal year with a strong liquidity position, holding $2.2 billion in cash and short-term investments.
- BD actively managed its capital structure, repurchasing $1.5 billion of its common stock and paying $368 million in dividends during fiscal year 2012.
- Significant legal proceedings, including antitrust litigation, are ongoing and pose a potential risk to the company's financial condition.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Becton Dickinson & Co kept $0.15.
- Revenue$7.71B100.0%
- Cost of revenue−$3.75B48.7%
- Gross profit$3.95B51.3%
- Operating costs−$2.40B31.1%
- Operating income$1.56B20.2%
- Interest, other & tax−$388.0M5.0%
- Net income$1.17B15.2%
Where FY2012 revenue went
$7.71B- Cost of revenue: $3.75B, 49% of revenue
- SG&A: $1.92B, 25% of revenue
- Net income: $1.17B, 15% of revenue
- R&D: $472.0M, 6.1% of revenue
- Interest, other & tax: $388.0M, 5.0% of revenue
Kept 15% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2012filed November 21, 2012Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $7.71B$7.58B | +1.6% |
| Cost of Revenue | $3.75B$3.63B | +3.6% |
| Gross Profit | $3.95B$3.96B | −0.2% |
| R&D Expenses | $472.00M$470.00M | +0.4% |
| SG&A Expenses | $1.92B$1.82B | +5.4% |
| Operating Expenses | $6.15B$5.92B | +3.9% |
| Operating Income | $1.56B$1.67B | −6.5% |
| Interest Expense | $135.00M$84.00M | +60.7% |
| Net Income | $1.17B$1.27B | −7.9% |
| EPS (Basic) | $5.69$5.75 | −1.0% |
| EPS (Diluted) | $5.59$5.62 | −0.5% |
| Shares Outstanding (Basic) | 205.46M221.18M | −7.1% |
| Shares Outstanding (Diluted) | 209.18M226.28M | −7.6% |
05—Questions
Frequently Asked Questions
What was BDX's overall financial performance in fiscal year 2012?
Becton, Dickinson and Company (BDX) reported total revenues of $7.7 billion for fiscal year 2012, representing a 1.6% increase compared to the prior year. The company's income from continuing operations was $1.11 billion, or $5.30 per diluted share. Despite challenging economic conditions, BD demonstrated resilience through strategic acquisitions and continued investment in its product lines.
What were the key growth drivers for BDX in 2012?
BD's revenue growth was primarily driven by new product launches and the successful integration of recent acquisitions, such as KIESTRA Lab Automation and Sirigen Group. Growth was also supported by increased sales of safety-engineered products and expansion in emerging markets, particularly within the BD Medical and BD Diagnostics segments.
What are the major risks and uncertainties facing BDX as highlighted in the filing?
BDX identified several key risks, including the impact of challenging global economic conditions on healthcare utilization and pricing, foreign currency exchange rate fluctuations due to significant international sales, changes in third-party reimbursement practices, and the consequences of U.S. healthcare reform, specifically the 2.3% excise tax on medical device manufacturers starting in 2013. Additionally, ongoing litigation poses a potential risk to operations and financial results.
How is BDX managing its capital and shareholder returns?
BD maintained a strong financial position with substantial cash reserves and actively returned capital to shareholders. In fiscal year 2012, the company repurchased approximately $1.5 billion of its common stock and paid cash dividends totaling $368 million. BD also reported a debt-to-capitalization ratio of 49.7% at the end of fiscal year 2012, indicating strategic use of debt financing.
06—Continue